“…Of particular interest is that 3-carboxamide analogues, especially 2b , have shown bioactivity against various Gram-positive bacteria including clinically resistant strains such as MRSA, fluoroquinolone-resistant S. aureus , MDRSP, penicillin and erythromycin-resistant S. pneumonia and VRE as well as Gram-negative H. influenzae . Further optimisation, especially for overcoming high plasma-protein binding, is warranted but these compounds may be suitable for an evaluation for topical use [31–32]. Significantly, these results suggest that a drug discovery approach based upon deconstruction–reconstruction inspired by suitable natural products with demonstrable biological activity provides a route for the rapid assembly of compound libraries, which, even if not fully optimized, provide a useful starting point for further elaboration.…”